Figure 1From: Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repairPhotomicrographs showing safranin O staining at 1 month after surgery. (a, b) The defect treated with bevacizumab. (c, d) The defect untreated as the control. Scale bars, 1 mm in (a) and (c) and 250 μm in (b) and (d).Back to article page